Strong worldwide demand for its MedSurg and Structural Heart lines, traction in United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive ...

For patients with atrial fibrillation who need protection from stroke and other complications after ablation, left atrial ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

At the moment, the company is developing novel therapeutic approaches for patients with underserved heart issues, such as ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

周一，TD Cowen对波士顿科学公司 (NYSE:BSX)股票表示积极态度，维持买入评级，目标价为$100.00。这一背书是基于Option研究的结果，该研究突显了Watchman设备的安全性和有效性。